Incyte Future Growth

Future criteria checks 3/6

Incyte is forecast to grow earnings and revenue by 17.8% and 8.6% per annum respectively. EPS is expected to grow by 17.3% per annum. Return on equity is forecast to be 18.4% in 3 years.

Key information

17.8%

Earnings growth rate

17.3%

EPS growth rate

Biotechs earnings growth	23.7%
Revenue growth rate	8.6%
Future return on equity	18.4%
Analyst coverage	Good
Last updated	02 May 2024

Recent future growth updates

Recent updates

Incyte drug Pemazyre to treat rare cancer cholangiocarcinoma approved in Australia

Sep 15

Incyte wins approval of Pemazyre for rare blood cancer

Aug 26

Incyte Q2 results beat on top and bottom lines as net income soars 27%; shares down 6%

Aug 02

With EPS Growth And More, Incyte (NASDAQ:INCY) Makes An Interesting Case

Jul 27

Incyte Corp. Should Move Higher (Technical Analysis)

Jul 18

Incyte: Growth Drivers Are Coming

Jun 17

Incyte Is A Buy As Ruxolitinib Ramps Revenue And Pipeline Matures

Apr 14

Incyte: All Atention On Opzelura

Mar 21

Incyte: Still Has Room To Grow

Jan 24

Incyte: The Right Time To Buy The Stock

Dec 28

Incyte: Not Exciting Yet, But Perhaps To Come

Aug 14

Earnings and Revenue Growth Forecasts

NasdaqGS:INCY - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	5,014	1,216	1,329	1,406	17
12/31/2025	4,517	963	1,067	1,172	20
12/31/2024	4,084	759	894	1,329	20
3/31/2024	3,768	745	791	821	N/A
12/31/2023	3,696	598	449	496	N/A
9/30/2023	3,609	425	566	632	N/A
6/30/2023	3,513	366	698	781	N/A
3/31/2023	3,470	324	561	649	N/A
12/31/2022	3,395	341	892	970	N/A
9/30/2022	3,331	876	711	802	N/A
6/30/2022	3,320	945	665	760	N/A
3/31/2022	3,115	933	609	759	N/A
12/31/2021	2,986	949	568	749	N/A
9/30/2021	2,913	535	543	741	N/A
6/30/2021	2,721	338	450	668	N/A
3/31/2021	2,703	478	569	765	N/A
12/31/2020	2,667	-296	-312	-125	N/A
9/30/2020	2,457	-335	-266	-100	N/A
6/30/2020	2,388	-191	-108	-12	N/A
3/31/2020	2,229	-376	-227	-128	N/A
12/31/2019	2,159	447	633	711	N/A
9/30/2019	2,108	405	589	663	N/A
6/30/2019	2,006	306	476	592	N/A
3/31/2019	1,997	253	392	471	N/A
12/31/2018	1,882	109	263	336	N/A
9/30/2018	1,798	-109	90	163	N/A
6/30/2018	1,729	-102	-66	17	N/A
3/31/2018	1,534	-167	-1	101	N/A
12/31/2017	1,536	-313	N/A	-93	N/A
9/30/2017	1,419	-155	N/A	91	N/A
6/30/2017	1,306	-154	N/A	133	N/A
3/31/2017	1,226	-107	N/A	34	N/A
12/31/2016	1,106	104	N/A	305	N/A
9/30/2016	1,023	151	N/A	280	N/A
6/30/2016	941	74	N/A	193	N/A
3/31/2016	858	49	N/A	189	N/A
12/31/2015	754	7	N/A	89	N/A
9/30/2015	634	-86	N/A	61	N/A
6/30/2015	644	13	N/A	81	N/A
3/31/2015	581	-33	N/A	53	N/A
12/31/2014	511	-48	N/A	26	N/A
9/30/2014	485	-54	N/A	-30	N/A
6/30/2014	372	-136	N/A	-70	N/A
3/31/2014	374	-101	N/A	-47	N/A
12/31/2013	355	-83	N/A	9	N/A
9/30/2013	372	-21	N/A	-1	N/A
6/30/2013	347	-21	N/A	-16	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: INCY's forecast earnings growth (17.8% per year) is above the savings rate (2.4%).

Earnings vs Market: INCY's earnings (17.8% per year) are forecast to grow faster than the US market (14.1% per year).

High Growth Earnings: INCY's earnings are forecast to grow, but not significantly.

Revenue vs Market: INCY's revenue (8.6% per year) is forecast to grow faster than the US market (8.2% per year).

High Growth Revenue: INCY's revenue (8.6% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: INCY's Return on Equity is forecast to be low in 3 years time (18.4%).

Incyte Future Growth

Future criteria checks 3/6

Key information

Recent future growth updates

Incyte Corporation Maintains Earnings Guidance for 2024

Incyte Corporation Provides Earnings Guidance for 2024

Incyte Corporation Provides Earning Guidance for the Full Year 2023

Incyte Corporation Revises Earnings Guidance for the Year 2023

Consensus EPS estimates increase by 21%

Price target decreased by 7.5% to US$82.42

Recent updates

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Incyte Corporation, Annual General Meeting, Jun 12, 2024

Incyte Corporation Maintains Earnings Guidance for 2024

Incyte Pharmaceuticals: Cheap Enough Now (Rating Upgrade)

Incyte Corporation (NasdaqGS:INCY) entered into a definitive agreement to acquire Escient Pharmaceuticals, Inc. from a group of shareholders for $750 million.

Incyte Corporation to Report Q1, 2024 Results on Apr 30, 2024

Incyte Announces New Results from A Phase 2 Study Evaluating the Efficacy and Safety of Twice-Daily Ruxolitinib Cream 1.5% (Opzelura®) in Adult Patients with Hurley Stage 1 or 2 (Mild-To-Moderate) Hidradenitis Suppurativa (HS)

Incyte: A Potential GARP Superstar

Incyte Corporation Provides Earnings Guidance for 2024

Full year 2023 earnings: Revenues and EPS in line with analyst expectations

Incyte Corporation to Report Q4, 2023 Results on Feb 13, 2024

Incyte and Syndax Pharmaceuticals Present Additional Data from Positive AGAVE-201 Trial at ASH Plenary Session Showing Axatilimab Efficacy Including Durable Responses in Chronic Graft-Versus-Host Disease

Incyte Corporation Provides Earning Guidance for the Full Year 2023

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Incyte Announces New Data for Ruxolitinib Cream (Opzelura®) in Children with Atopic Dermatitis

Incyte Announces Positive 52-Week Data from Phase 2b Study Evaluating Povorcitinib (INCB54707) in Patients with Extensive Nonsegmental Vitiligo

Incyte Corporation to Report Q3, 2023 Results on Oct 31, 2023

Incyte Corporation Announces Executive Changes, Effective November 1, 2023

Executive VP & Chief Medical Officer recently sold US$1.4m worth of stock

Executive VP & Chief Medical Officer notifies of intention to sell stock

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Incyte Corporation Revises Earnings Guidance for the Year 2023

Consensus EPS estimates increase by 21%

Syndax Pharmaceuticals and Incyte Announce Positive Topline Results from the Pivotal Agave-201 Trial of Axatilimab in Chronic Graft-Versus-Host Disease

Incyte Corporation to Report Q2, 2023 Final Results on Aug 01, 2023

Price target decreased by 7.5% to US$82.42

Incyte Corporation Appoints Pablo J. Cagnoni, M.D. as President and Head of Research & Development, Effective June 5, 2023

Consensus EPS estimates fall by 12%

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Executive VP & Chief Scientific Officer exercised options to buy US$287k worth of stock.

Incyte Announces 52-Week Results from Phase 2 Study Evaluating Povorcitinib (INCB54707) in Patients with Hidradenitis Suppurativa

Incyte Corporation Provides Earnings Guidance for the Year 2023

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Here's Why We Think Incyte (NASDAQ:INCY) Might Deserve Your Attention Today

Insider exercised options and sold US$115k worth of stock

Incyte Corporation to Report Q4, 2022 Results on Feb 07, 2023

Executive VP & Chief Medical Officer notifies of intention to sell stock

Insider notifies of intention to sell stock

Incyte Announces Data from Two LIMBER Studies Evaluating Combination Treatments in Patients with Myelofibrosis

Syndax Pharmaceuticals and Incyte Announce Axatilimab Phase 1/2 Data in Patients with Chronic Graft-Versus-Host Disease Published in the Journal of Clinical Oncology

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Here's Why We Think Incyte (NASDAQ:INCY) Might Deserve Your Attention Today

Incyte Corporation Announces Pivotal Phase 3 Data Showing Significant Improvements in Facial and Total Body Repigmentation with Ruxolitinib Cream (Opzelura™) in Vitiligo Published in New England Journal of Medicine

Incyte Corporation to Report Q3, 2022 Results on Nov 01, 2022

Knight's affiliate files for Brazilian approval of cancer drug tafasitamab

Incyte Announces the Appointment of Susanne Schaffert as New Member of Its Board of Directors

Incyte Corporation (NasdaqGS:INCY) entered into an agreement to acquire Villaris Therapeutics, Inc. from Medicxi Ventures (UK) LLP and others for $1.4 billion.

Incyte: A Biotech Stock With Improving Growth Prospects And A Favorable Chart

Incyte drug Pemazyre to treat rare cancer cholangiocarcinoma approved in Australia

Incyte Corporation Announces FDA Approval Of Pemazyre® (Pemigatinib) As The First And Only Targeted Treatment For Myeloid/Lymphoid Neoplasms (MLNs) With FGFR1 Rearrangement

Incyte wins approval of Pemazyre for rare blood cancer

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Incyte Corporation Reaffirms Revenue Guidance for the Full Year 2022

Incyte Q2 results beat on top and bottom lines as net income soars 27%; shares down 6%

With EPS Growth And More, Incyte (NASDAQ:INCY) Makes An Interesting Case

Incyte Corporation Announces U.S. FDA Approval of Opzelura Cream for the Treatment of Vitiligo

Incyte Corp. Should Move Higher (Technical Analysis)

Incyte Corporation to Report Q2, 2022 Results on Aug 02, 2022

Insider notifies of intention to sell stock

Incyte: Growth Drivers Are Coming

FDA Approves Eli Lilly and Company and Incyte's OLUMIANT® (baricitinib) as First and Only Systemic Medicine for Adults with Severe Alopecia Areata

Chmp Recommends Approval of Eli Lilly and Company and Incyte's Olumiant® (Baricitinib) as the First and Only Centrally-Authorized Treatment for Adults with Severe Alopecia Areata (Aa)

FDA Approves Lilly and Incyte's OLUMIANT® (baricitinib) for the Treatment of Certain Hospitalized Patients with COVID-19

Incyte Announces European Commission Approval of Jakavi (Ruxolitinib) as the First Post-Steroid Treatment for Acute and Chronic Graft-Versus-Host Disease

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Incyte Corporation, Annual General Meeting, Jun 15, 2022

Incyte Announces Positive Committee for Medicinal Products Opinion for Capmatinib (Tabrecta®) for the Treatment of Metex14 Advanced Non-Small Cell Lung Cancer

Insider notifies of intention to sell stock

Executive VP & GM of North America notifies of intention to sell stock